Autologous T cell therapy targeting multiple antigens shows promise in treating pancreatic cancer

A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising ...
The American Journal of Managed Care

Amivantamab Plus FOLFOX/FOLFIRI Demonstrates Strong, Durable Activity in mCRC

Amivantamab combined with FOLFOX or FOLFIRI showed a 51% overall response rate in RAS/BRAF wild-type mCRC patients, with a ...